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Abstract: 14-3-3 proteins are abundant, intramolecular proteins that play a pivotal role in cellular
signal transduction by interacting with phosphorylated ligands. In addition, they are molecular
chaperones that prevent protein unfolding and aggregation under cellular stress conditions in a
similar manner to the unrelated small heat-shock proteins. In vivo, amyloid β (Aβ) and α-synuclein
(α-syn) form amyloid fibrils in Alzheimer’s and Parkinson’s diseases, respectively, a process that
is intimately linked to the diseases’ progression. The 14-3-3ζ isoform potently inhibited in vitro
fibril formation of the 40-amino acid form of Aβ (Aβ40) but had little effect on α-syn aggregation.
Solution-phase NMR spectroscopy of 15N-labeled Aβ40 and A53T α-syn determined that unlabeled
14-3-3ζ interacted preferentially with hydrophobic regions of Aβ40 (L11-H21 and G29-V40) and α-syn
(V3-K10 and V40-K60). In both proteins, these regions adopt β-strands within the core of the amyloid
fibrils prepared in vitro as well as those isolated from the inclusions of diseased individuals. The
interaction with 14-3-3ζ is transient and occurs at the early stages of the fibrillar aggregation pathway
to maintain the native, monomeric, and unfolded structure of Aβ40 and α-syn. The N-terminal
regions of α-syn interacting with 14-3-3ζ correspond with those that interact with other molecular
chaperones as monitored by in-cell NMR spectroscopy.
Keywords: 14-3-3 proteins; molecular chaperone; amyloid β; α-synuclein; NMR spectroscopy;
amyloid fibril
1. Introduction
Protein aggregation is a characteristic of many diseases, the majority of which are
age-related and neurological. Common examples of protein aggregation diseases (also
known as protein misfolding or protein conformational diseases) include Alzheimer’s
(AD), Parkinson’s (PD), Huntington’s, and Creutzfeldt–Jakob [1,2]. The protein aggregates
or deposits associated with these diseases contain a predominant peptide or protein that, in
the majority of cases, adopts an amyloid fibrillar form. Amyloid fibrils are a highly stable,
aggregated proteinaceous state with the polypeptide arranged mainly in a cross β-sheet
conformation that results in an extended, overall fibrillar structure up to micrometers in
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length [1,2]. The conversion of a protein from its native, functional state to an amyloid
fibril is a multi-step process that usually involves a nucleation-dependent mechanism that
has various intermediate states, including the formation of prefibrillar oligomers that act
as nuclei to sequester and convert natively structured proteins into the fibrillar form. The
prefibrillar oligomers are proposed to be the entities that cause cell toxicity and, hence, are
intimately involved in the disease processes [1,2].
Within and outside cells, protein levels and their conformations are maintained within
a narrow regime to minimize the possibility of protein unfolding, misfolding, and aggre-
gation. The general term for this process is proteostasis, a portmanteau of protein and
homeostasis [3]. The action of molecular chaperone proteins in stabilizing the conformation,
stoichiometry, and interactions of other proteins is one of the major means of maintaining
cellular proteostasis. Under stress conditions such as elevated temperature, the principal
intracellular chaperones that function to prevent protein unfolding and aggregation are the
small heat-shock proteins (sHsps) [4]. Their levels are upregulated many-fold under such
conditions and with aging [4] and in diseases associated with protein aggregation [5,6].
Overall, the ATP-independent action of sHsps is crucially important in cellular well-being
under normal and stress conditions.
In addition to sHsps, other proteins have an sHsp-like chaperone ability that may
supplement or complement that of sHsps. In this context, intracellular 14-3-3 proteins
exhibit chaperone action against a variety of unfolding proteins under stress conditions
such as elevated temperature [7–10]. They are present at high levels in the brain. In
humans, there are seven closely related 14-3-3 proteins. The principal role of 14-3-3 proteins
is their involvement in cellular signal transduction processes via their interaction with
phosphorylated substrate proteins. As such, they function as adapters and participate in a
variety of cellular pathways, including apoptosis, transcription and the stress response [9].
In addition to their intracellular presence, 14-3-3 proteins are found extracellularly, for
example in exosomes and in cerebrospinal fluid of people with neurodegenerative diseases
such as Creutzfeldt–Jakob disease, AD, and multiple sclerosis [11]. 14-3-3 proteins are
dimers composed of subunits of ~28 kDa in mass. Each subunit adopts a predominantly
α-helical conformation with nine α-helices. The dimer is arranged in a double cup-like
shape with two amphipathic binding grooves where phosphorylated ligands bind. The
dimer interface is provided by an interaction between N-terminal helices of each subunit.
The two major neurological diseases associated with protein aggregation and deposi-
tion are AD and PD [1,2]. AD is characterized by the extracellular deposition of plaques
containing mainly variants of the amyloid beta peptide (Aβ) in an amyloid fibrillar form,
along with intracellular neurofibrillary tangles containing mainly the tau protein. The
principal Aβ peptides are 40 and 42 amino acids in length. In PD, Lewy body deposits are
the defining morphological intracellular feature; they are mainly comprised of the protein
α-synuclein (α-syn), also deposited as amyloid fibrils. In AD and PD, other proteins are as-
sociated with these deposits, including sHsps and 14-3-3 proteins [9,12,13]. Their presence
may arise from the utilization by cells of their chaperone ability as an attempt to prevent
the aggregation of Aβ and α-syn to form amyloid fibrils.
In this study, we report on an NMR spectroscopic and biophysical analysis of the
interaction of 14-3-3ζ, a major 14-3-3 isoform, with Aβ, and a similar interaction between
14-3-3ζ and A53T α-syn, a mutant of α-syn associated with familial PD that aggregates
more rapidly than the wild type (WT) protein. The findings have implications for the
in vivo association of these species and their involvement in AD, PD, and other related
diseases of protein aggregation where amyloid fibrillar aggregation occurs.
2. Results and Discussion
2.1. Interaction of 14-3-3ζ with Amyloid β Peptides
Thioflavin T (ThT) is a dye whose fluorescence increases markedly upon binding to
the β-sheet regions of amyloid fibrils, a phenomenon that is routinely utilized to monitor
amyloid fibril formation in peptides and proteins [14]. Figure 1 shows the ThT fluorescence
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profiles for the 40- and 42-amino acid forms of Aβ (Aβ40 and Aβ42, respectively) with
time in the absence and presence of increasing quantities of 14-3-3ζ. The Aβ42 peptide is
more hydrophobic than Aβ40 due to the presence of the additional Ile-Ala dipeptide at its
C-terminus. Consistent with the observation by others [15], Aβ42 aggregates at a much
faster rate (compare Figure 1a,b, noting the very different time scales), without the presence
of a lag phase, compared to Aβ40 which has a very long lag phase of around 33 h under the
conditions used. The protein 14-3-3ζwas much more effective at inhibiting the aggregation
of Aβ40 than Aβ42. Thus, a 1.0:0.5 molar subunit ratio of Aβ40:14-3-3ζ completely inhibited
the former’s aggregation (Figure 1a) whereas a two-molar excess of 14-3-3ζ only partially
reduced fibril formation of Aβ42 (Figure 1b). In separate experiments, Aβ40 that had been
seeded with Aβ40 fibrils aggregated much earlier, i.e., a lag phase of 12 h (Figure S1). An
equimolar ratio of Aβ40:14-3-3ζ significantly delayed the onset of Aβ40 aggregation (lag
phase of 29 h) and partially suppressed its extent of aggregation as monitored by ThT
fluorescence. More pronounced effects on the lag phase and extent of Aβ40 fibril formation
were observed at a 1.0:2.0 molar ratio, with complete inhibition of aggregation occurring at
a 1.0:4.0 molar ratio of Aβ40:14-3-3ζ (Figure S1).




Figure 1. The molecular chaperone ability of 14-3-3ζ to inhibit amyloid fibril formation of Aβ40 and Aβ42. Amyloid fibril 
formation, as monitored by ThT fluorescence, of 15 μM Aβ40 (A) and Aβ42 (B) at 37 °C in the absence (black circles) and 
presence of 14-3-3ζ at 1.0:0.5 (brown triangles; Aβ40 only), 1:1 (red crosses), and 1:2 (blue diamonds) molar ratios of 
Aβ40/Aβ42:14-3-3ζ. Also shown is 14-3-3ζ incubated alone at 30 µM (beige squares). On the right of part (A) are TEM images 
of Aβ40 in the absence and presence of 14-3-3ζ at a 1.0:0.5 molar ratio of Aβ40:14-3-3ζ. Samples for TEM imaging were taken 
upon completion of the aggregation assay after 150 h of incubation. On the right of part (B) are TEM images of Aβ42 in the 
absence and presence of 14-3-3ζ at an equimolar ratio. Each image was acquired from the samples after 200 min. of incu-
bation. Scale bars in all images represent 1 μm. 
Figure 2a shows the 1H-15N HSQC spectrum of 15N-labeled Aβ40 at physiological pH 
and 5 °C, in the absence and presence of unlabeled 14-3-3ζ, at up to a four-molar excess of 
the chaperone protein. The NMR experiments were conducted at a low temperature to 
negate (or minimize) the possibility that Aβ40 would form amyloid fibrils during the 
timeframe of acquisition of the spectra. Thus, the NMR experiments monitored interac-
tions between Aβ40 and 14-3-3ζ at the earliest stage of Aβ40 amyloid fibril formation. 
Cross-peaks of Aβ40 are labeled in Figure 2a [24]. Cross-peaks were not observed for 
six of the 40 amino acids of Aβ40 (D1, A2, H6, D7, H14 and K28), presumably due to broad-
ening associated with intermediate exchange. No change in chemical shifts of the ob-
served cross-peaks occurred in the presence of 14-3-3ζ, implying weak and transient in-
teractions and a relatively overall fast exchange between the two species. There was a non-
uniform decrease in the intensity, or broadening, of the Aβ40 cross-peaks across its amino 
acid sequence in the presence of increasing concentrations of 14-3-3ζ compared to the 
spectrum of Aβ40 on its own (Figure 2b). The decrease in cross-peak intensity was most 
marked for Q15 to G25, encompassing the hydrophobic core of the peptide (L17-V18-F19-
F20-A21), and most of the cross-peaks arising from the C-terminal region Aβ40 (G29 to 
V40), which is also hydrophobic in character. The NMR data imply that these regions in-
teract with 14-3-3ζ during its chaperone function to inhibit Aβ40 amyloid fibril formation. 
As with the chaperone mechanism of the sHsp αB-crystallin in preventing amyloid fibril 
formation of Aβ40 [25], the interaction between the 14-3-3ζ and Aβ40 is transient in nature, 
which facilitates the potent stoichiometry of 14-3-3ζ in inhibiting Aβ40 aggregation.  
Figure 1. The molecular chaperone abil ty of 14-3-3ζ to inhibit amyloid fibril formation of Aβ40 and Aβ42. Amyloid fibril
formation, as it re fl resce ce, f 15 µ Aβ40 (A) and Aβ42 (B) at 37 ◦C in the absence (black circles)
and presence of 14-3-3ζ at 1.0:0.5 (brown triangles; Aβ40 only), 1:1 (red crosses), and 1:2 (blue diamonds) molar ratios of
Aβ40/Aβ42:14-3-3ζ. Also shown is 14-3-3ζ incubated alone at 30 µM (beige squares). On the right of part (A) are TEM
images of Aβ40 in the absence and presence of 14-3-3ζ at a 1.0:0.5 molar ratio of Aβ40:14-3-3ζ. Samples for TEM imaging
were taken upon completion of the aggregation assay after 150 h of incubation. On the right of part (B) are TEM images of
Aβ42 in the absence and presence of 14-3-3ζ at an equimolar ratio. Each image was acquired from the samples after 200 min.
of incubation. Scale bars in all images represent 1 µm.
Transmission electron microscopy (TEM) images confirmed the conclusions from the
ThT data of Figure 1. In the absence of 14-3-3ζ, both Aβ peptides formed amyloid fibrils,
with Aβ40 fibrils being longer than those of Aβ42 (compare Figure 1a,b). TEM images of
Aβ42 showed agglomerates of fibrils alongside well-separated, distinct fibrillar species
(Figure 1b). In the presence of 14-3-3ζ, the formation of amorphous-like aggregates was
observed for both Aβ peptides, a phenomenon that commonly occurs when fibril-inhibiting
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molecules (large and small) interact with amyloid fibril-forming peptides and proteins
(e.g., [16]). In summary, 14-3-3ζ inhibited the aggregation and fibril formation of Aβ40 at
stoichiometric ratios. By contrast, 14-3-3ζ only partially inhibited the aggregation of Aβ42
at these ratios.
Other studies have examined the in vitro chaperone ability of 14-3-3ζ against amor-
phously aggregating target proteins [7,8,10]. 14-3-3ζ is unlike sHsps as it is not highly
promiscuous in its chaperone ability, i.e., 14-3-3ζ exhibits relatively selective chaperone
ability against aggregating target proteins. However, like sHsps [17–20], 14-3-3ζ is a more
efficient chaperone at inhibiting target proteins that are aggregating slowly and amor-
phously. Thus, target protein aggregation rate (i.e., kinetics) may be the major factor in
determining the greater ability of 14-3-3ζ to inhibit the aggregation of Aβ40 more efficiently
compared to the aggregation of Aβ42. The poorer efficiency of 14-3-3ζ at inhibiting the
amyloid fibril formation of seeded Aβ40 (Figure S1), in which faster aggregation of the
peptide occurred than for unseeded Aβ40 (Figure 1a), is consistent with this conclusion.
Likewise, sHsps are more efficient at inhibiting slowly aggregating amyloid fibril-forming
target proteins such as α-syn [12,21]. According to Mori et al. and Kollmer et al., Aβ40 is
the major secreted form of the Aβ peptides in vivo and is the predominant species present
in AD extracellular plaques [22,23]. The presence of 14-3-3 proteins extracellularly [11],
where Aβ peptides are primarily located, implies that the ability of 14-3-3ζ to inhibit Aβ40
aggregation has physiological significance. Accordingly, the residue-specific interaction
between Aβ40 and 14-3-3ζwas explored by solution-phase NMR spectroscopy.
Figure 2a shows the 1H-15N HSQC spectrum of 15N-labeled Aβ40 at physiological pH
and 5 ◦C, in the absence and presence of unlabeled 14-3-3ζ, at up to a four-molar excess
of the chaperone protein. The NMR experiments were conducted at a low temperature
to negate (or minimize) the possibility that Aβ40 would form amyloid fibrils during the
timeframe of acquisition of the spectra. Thus, the NMR experiments monitored interactions
between Aβ40 and 14-3-3ζ at the earliest stage of Aβ40 amyloid fibril formation.




Figure 2. 1H-15N HSQC NMR spectrum of uniformly 15N-labeled Aβ40 in the absence and presence of 14-3-3ζ. (A). Amide 
region of the 1H-15N HSQC spectrum at 5 °C of 15N-labeled Aβ40 in the presence of unlabeled 14-3-3ζ at 1.0:0.0–4.0 molar 
ratios of Aβ40:14-3-3ζ (red contour levels: 0.0, orange: 0.5, green: 1.0, blue: 2.0, and purple: 4.0 refer to the molar ratio of 
14-3-3ζ to Aβ40). Assignments are from Hou and Zagorski [24]. No change in the 1H and 15N chemical shifts of Aβ40 oc-
curred upon addition of 14-3-3ζ. (B). The change in the relative intensities of Aβ40 1H-15N cross-peaks at 1.0:0.5-4.0 molar 
ratios of Aβ40:14-3-3ζ relative to Aβ40 alone (orange line). The intensities of the contour levels were corrected for dilution 
effects. Error bars represent the standard deviation in background noise of the spectra. 
The recent determination of the structures of the amyloid fibrillar forms of Aβ pep-
tides by cryo-electron microscopy (cryoEM) has provided an atomic-level description of 
the arrangement of the polypeptide backbone. Of most relevance is the cryoEM structure 
of Aβ40 fibrils isolated from the brain tissue of AD patients, post-mortem [23]. From this 
study, the four β-strands in the β-sheet fibril core of Aβ40 arise from residues A2-S8, Y10-
H13, Q15-F19, and I32-L34. The latter two β-strands correspond well to the residues 
whose cross-peak intensities in the 1H-15N NMR spectrum of Aβ40 are decreased in the 
presence of 14-3-3ζ (Figure 2b). They also correspond well to the residues that form the 
cross β-sheet core of Aβ, as determined by solid state NMR spectroscopy [26,27]. Further-
more, of all the Aβ40 cross-peaks in Figure 2b, the intensity of the Q15 cross-peak was 
decreased the most (by over 20%) in the presence of a four-molar excess of 14-3-3ζ. Thus, 
14-3-3ζ interacts preferentially with at least part of the Aβ40 peptide that forms its fibril 
core and, since it does so with Aβ40 amino acids within and nearby to Q15-F19 and I32-
L34, it is surmised that these two β-strands are potentially the first to assemble during 
Aβ40 fibril formation. Furthermore, 14-3-3ζ inhibits Aβ40 fibril formation via interfering at 
the earliest stage of its aggregation pathway. Again, this mechanism has distinct parallels 
with that exhibited by sHsps during their prevention of amyloid fibril formation of a va-
riety of proteins (summarized in [5,6,28]). Although Aβ-containing amyloid plaques are 
extracellular deposits, there is an intracellular component to Aβ aggregation prior to the 
peptide’s export into the extracellular medium [29]. Thus, in vivo interaction of Aβ with 
14-3-3ζ intracellularly, along with the other 14-3-3 isoforms and sHsps, may have physio-
logical importance in modulating Aβ aggregation and maintaining intracellular proteo-
stasis. Furthermore, the extracellular presence of 14-3-3 proteins [11] would also provide 
the opportunity for their interaction with Aβ in this environment. 
  
. 5N HSQC R spectr of if r l 5N-labeled Aβ40 in the absence and presence of 14-3-3ζ. (A) i
re i f t e 1 - S s ectr at 5 ◦C of 15N-labeled Aβ40 in the presence of unlabeled 14-3-3ζ at 1.0:0.0–4.0 molar
ratios of Aβ40:14-3-3ζ (red contour levels: 0.0, orange: 0.5, green: 1.0, blue: 2.0, and purple: 4.0 refer to the molar ratio
of 14-3-3ζ to Aβ40). Assignments are from Hou and Zagorski [24]. No change in the 1H and 15N chemical shifts of Aβ40
occurred upon addition of 14-3-3ζ. (B) The change in the relative intensities of Aβ40 1H-15N cross-peaks at 1.0:0.5-4.0 molar
ratios of Aβ40:14-3-3ζ relative to Aβ40 alone (orange line). The intensities of the contour levels were corrected for dilution
effects. Error bars represent the standard deviation in background noise of the spectra.
Cross-peaks of Aβ40 are labeled in Figure 2a [24]. Cross-peaks were not observed
for six of the 40 amino acids of Aβ40 (D1, A2, H6, D7, H14 and K28), presumably due to
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broadening associated with intermediate exchange. No change in chemical shifts of the
observed cross-peaks occurred in the presence of 14-3-3ζ, implying weak and transient
interactions and a relatively overall fast exchange between the two species. There was a
non-uniform decrease in the intensity, or broadening, of the Aβ40 cross-peaks across its
amino acid sequence in the presence of increasing concentrations of 14-3-3ζ compared to
the spectrum of Aβ40 on its own (Figure 2b). The decrease in cross-peak intensity was
most marked for Q15 to G25, encompassing the hydrophobic core of the peptide (L17-V18-
F19-F20-A21), and most of the cross-peaks arising from the C-terminal region Aβ40 (G29
to V40), which is also hydrophobic in character. The NMR data imply that these regions
interact with 14-3-3ζ during its chaperone function to inhibit Aβ40 amyloid fibril formation.
As with the chaperone mechanism of the sHsp αB-crystallin in preventing amyloid fibril
formation of Aβ40 [25], the interaction between the 14-3-3ζ and Aβ40 is transient in nature,
which facilitates the potent stoichiometry of 14-3-3ζ in inhibiting Aβ40 aggregation.
The recent determination of the structures of the amyloid fibrillar forms of Aβ peptides
by cryo-electron microscopy (cryoEM) has provided an atomic-level description of the
arrangement of the polypeptide backbone. Of most relevance is the cryoEM structure of
Aβ40 fibrils isolated from the brain tissue of AD patients, post-mortem [23]. From this study,
the four β-strands in the β-sheet fibril core of Aβ40 arise from residues A2-S8, Y10-H13,
Q15-F19, and I32-L34. The latter two β-strands correspond well to the residues whose
cross-peak intensities in the 1H-15N NMR spectrum of Aβ40 are decreased in the presence
of 14-3-3ζ (Figure 2b). They also correspond well to the residues that form the cross β-
sheet core of Aβ, as determined by solid state NMR spectroscopy [26,27]. Furthermore, of
all the Aβ40 cross-peaks in Figure 2b, the intensity of the Q15 cross-peak was decreased
the most (by over 20%) in the presence of a four-molar excess of 14-3-3ζ. Thus, 14-3-3ζ
interacts preferentially with at least part of the Aβ40 peptide that forms its fibril core
and, since it does so with Aβ40 amino acids within and nearby to Q15-F19 and I32-L34,
it is surmised that these two β-strands are potentially the first to assemble during Aβ40
fibril formation. Furthermore, 14-3-3ζ inhibits Aβ40 fibril formation via interfering at the
earliest stage of its aggregation pathway. Again, this mechanism has distinct parallels
with that exhibited by sHsps during their prevention of amyloid fibril formation of a
variety of proteins (summarized in [5,6,28]). Although Aβ-containing amyloid plaques
are extracellular deposits, there is an intracellular component to Aβ aggregation prior to
the peptide’s export into the extracellular medium [29]. Thus, in vivo interaction of Aβ
with 14-3-3ζ intracellularly, along with the other 14-3-3 isoforms and sHsps, may have
physiological importance in modulating Aβ aggregation and maintaining intracellular
proteostasis. Furthermore, the extracellular presence of 14-3-3 proteins [11] would also
provide the opportunity for their interaction with Aβ in this environment.
2.2. Interaction of 14-3-3ζ with α-Synuclein
A53T α-syn is a mutant that aggregates at a faster rate compared to the WT protein
and is associated with familial PD [30]. As monitored by ThT fluorescence, 14-3-3ζ had
minimal ability to inhibit amyloid fibril formation of A53T α-syn at an equimolar ratio
under physiological conditions of over 22 h of co-incubation (Figure S2). In agreement
with this, Plotegher et al. [31] investigated the ability of all seven human 14-3-3 isoforms to
inhibit α-syn fibril formation and found that two of the isoforms (η and τ (also termed θ))
were potent inhibitors of α-syn aggregation, whereas the others, including 14-3-3ζ, were
ineffective. The inability of 14-3-3ζ to decrease A53T α-syn aggregation to any significant
degree at a stoichiometric ratio may be due to the latter protein’s relatively rapid rate of
aggregation, which commences around four hours of incubation compared to 33 h for
the Aβ40 peptide (Figure 1a). The selective nature of 14-3-3ζ chaperone action against
aggregating target proteins is also a factor since only the 14-3-3 η and τ/θ isoforms inhibit
α-syn aggregation [31]. TEM images of A53T α-syn amyloid fibrils formed in the absence
and presence of 14-3-3ζ were of very similar length and morphology, consistent with
the inability of 14-3-3ζ to modify A53T α-syn fibril formation (Figure S2). Atomic force
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microscopic analysis of amyloid fibrils produced from incubated mixtures of α-syn and
14-3-3ζ also showed little difference in fibril morphology compared to that of mature α-syn
amyloid fibrils [31].
A quartz crystal microbalance (QCM) measures the mass change of a surface upon
the addition or removal of molecules as monitored by the change in frequency of a quartz
crystal resonator. QCM was used to monitor the change in mass of WT α-syn preformed
amyloid fibrils attached to the crystal upon flowing solutions of monomeric α-syn, an
equimolar ratio of α-syn:14-3-3ζ and 14-3-3ζ itself over the crystal. The rate of change of
frequency was essentially the same for the addition of α-syn in the absence or presence
of 14-3-3ζ (Figure 3a), indicating that α-syn monomers bound to the α-syn fibrils on the
crystal surface (thus increasing their size and mass), a process that was not affected by
the presence of 14-3-3ζ. 14-3-3ζ did not bind to the α-syn fibrils. Thus, if any interaction
between the two proteins occurs, it does so early along the aggregation pathway of α-syn,
as with the interaction between α-syn and the sHsp, αB-crystallin [32,33]. The dynamic
light scattering (DLS) profiles of WT α-syn and 14-3-3ζwere similar, with hydrodynamic
radii at 37 ◦C and pH 7 of 2.789 ± 0.003 nm for WT α-syn and 2.818 ± 0.003 nm for
14-3-3ζ. The latter value compares well with the literature [8,34]. When both proteins were
mixed together at an equimolar ratio, however, a single peak was observed at the larger
hydrodynamic radius of 3.062 ± 0.001 nm (Figure 3b), implying some association between
the two proteins under physiological conditions.




Figure 3. (A). QCM traces of the elongation of preformed WT α-syn amyloid fibrils in the presence and absence of 14-3-
3ζ. Preformed amyloid fibrils were attached on to the chip and equilibrated with buffer for 24 h. At approximately 5000 s 
intervals, 10 μM WT α-syn monomer (red), 1.0:1.0 molar ratio of α-syn monomer:14-3-3ζ (pink), and 10 μM 14-3-3ζ (blue) 
were added. After the addition of each protein sample, the chip was washed with buffer until a plateau in signal was 
obtained (white). The rate of frequency change (R) is indicated for when α-syn monomer and a 1.0:1.0 molar ratio of α-
syn:14-3-3ζ were washed over the QCM crystal. (B). DLS of WT α-syn and 14-3-3ζ. DLS profile and hydrodynamic radius 
of 20 μM WT α-syn at 25 °C in the absence (red dashed line) and presence (pink continuous line) of 14-3-3ζ at a 1.0:1.0 
molar ratio. Also shown is the DLS profile of 20 μM 14-3-3ζ (blue dotted line). 
Accordingly, the interaction of α-syn and 14-3-3ζ was investigated by NMR spectros-
copy at pH 7.4 and 10 °C using 15N-labeled A53T α-syn in the presence of unlabeled 14-3-
3ζ at 1:1 and 1:2 molar ratios of A53T α-syn:14-3-3ζ. As with the interaction between Aβ40 
and 14-3-3ζ, the NMR experiments were acquired at a low temperature to circumvent the 
possibility of fibril formation by A53T α-syn. Figure 4a shows the 1H-15N HSQC NMR 
spectrum of A53T α-syn under these conditions. The 1H NH chemical shifts are all con-
tained within the ‘random coil’ chemical shift regime of 7.6 to 8.6 ppm, as expected since 
α-syn is a 140-amino acid intrinsically disordered protein of little or no stable secondary 
structure. In the presence of unlabeled 14-3-3ζ, no alteration in chemical shifts occurred 
of the α-syn cross-peaks. This was also observed for the 1H-15N HSQC NMR spectrum of 
a mixture of α-syn and 14-3-3η [31] and for α-syn interacting with αB-crystallin [32] and 
an unrelated molecular chaperone, Hsp70 [35]. The intensities of the cross-peaks in the 
HSQC spectra of A53T α-syn in the presence of 14-3-3ζ were measured, and their intensi-
ties relative to those in the spectrum of A53T α-syn only are plotted in Figure 4b. Altera-
tion in cross-peak intensity was localized to the N-terminus (V3 to K10) and from V40 to 
K60, and possibly towards the C-terminus between D121 and D135. Together, these data 
imply that the interaction between A53T α-syn and 14-3-3ζ is weak and transient, with 
fast exchange. In their NMR studies of the interaction of α-syn with 14-3-3η, Plotegher et 
al. [31] did not examine the effects on the intensity of α-syn cross-peaks due to the pres-
ence of 14-3-3η. In contrast to the results presented herein with 14-3-3ζ, 14-3-3η was an 
effective inhibitor of α-syn amyloid fibril formation [31]. Overall, the results from both 
studies are consistent with a transient and weak interaction between the two proteins 
which, owing to some subtle structural and mechanistic differences between isoforms, 
leads to inhibition of α-syn oligomerization in the presence of 14-3-3η but not 14-3-3ζ. 
Figure 3. (A) QCM traces of the elongation of preformed WT α-syn amyloid fibrils in the presence and absence of 14-3-3ζ.
Preformed amyloid fibrils were attached on to the chip and equilibrated with buffer for 24 h. At approximately 5000 s
intervals, 10 µM WT α-syn monomer (red), 1.0:1.0 molar ratio of α-syn monomer:14-3-3ζ (pink), and 10 µM 14-3-3ζ (blue)
were added. After the addition of each protein sample, the chip was washed with buffer until a plateau in signal was
obtained (white). The rate of frequency change (R) is indicated for when α-syn monomer and a 1.0:1.0 molar ratio of
α-syn:14- -3ζ were washed over the QCM crystal. (B) DLS of WT α-syn and 14-3-3ζ. DLS profile and hydr ic r i s
0 µ WT α-syn at 25 ◦C in the absence (red dashed line) and presence (pink continuous line) of 14-3-3ζ at a 1.0:1.0 molar
ratio. Also shown is the DLS profile of 20 µM 14-3-3ζ (blue dotted line).
i l , t e interaction of α-syn and 14- -3ζ was investigated by NMR spec-
troscopy at pH 7.4 and 10 ◦C using 15N-labeled A53T α-syn in the pr sence of unlabeled
14-3-3ζ at 1:1 and 1:2 molar ratios of A53T α-syn:14-3-3ζ. As with the interaction between
Aβ40 and 14-3-3ζ, the NMR experiments were acquired at a low temperature to circumvent
the possibility of fibril formation by A53T α-syn. Figure 4a shows the 1 -15N S
spectru of 53T α-syn under these conditions. The 1 che ical shifts are all con-
tained ithin the ‘rando coil’ che ical shift regi e of 7.6 to 8.6 pp , as expected since
α-syn is a 140-amino acid intrinsically disordered protein of little or no stable secondary
structure. In the presence of unlabeled 14-3-3ζ, no alteration in chemical shifts occurred of
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the α-syn cross-peaks. This was also observed for the 1H-15N HSQC NMR spectrum of
a mixture of α-syn and 14-3-3η [31] and for α-syn interacting with αB-crystallin [32] and
an unrelated molecular chaperone, Hsp70 [35]. The intensities of the cross-peaks in the
HSQC spectra of A53T α-syn in the presence of 14-3-3ζwere measured, and their intensities
relative to those in the spectrum of A53T α-syn only are plotted in Figure 4b. Alteration in
cross-peak intensity was localized to the N-terminus (V3 to K10) and from V40 to K60, and
possibly towards the C-terminus between D121 and D135. Together, these data imply that
the interaction between A53T α-syn and 14-3-3ζ is weak and transient, with fast exchange.
In their NMR studies of the interaction of α-syn with 14-3-3η, Plotegher et al. [31] did not
examine the effects on the intensity of α-syn cross-peaks due to the presence of 14-3-3η. In
contrast to the results presented herein with 14-3-3ζ, 14-3-3ηwas an effective inhibitor of
α-syn amyloid fibril formation [31]. Overall, the results from both studies are consistent
with a transient and weak interaction between the two proteins which, owing to some
subtle structural and mechanistic differences between isoforms, leads to inhibition of α-syn
oligomerization in the presence of 14-3-3η but not 14-3-3ζ.




Figure 4. 1H-15N HSQC NMR spectrum of uniformly 15N-labeled A53T α-syn in the absence and presence of 14-3-3ζ. (A). 
Amide region of the 1H-15N HSQC spectrum at 10 °C of 15N-labeled A53T α-syn (black) following the addition of one 
(green) and two (red) molar equivalents of unlabeled 14-3-3ζ. Assignments are from Dedmon et al. [35]. No change in the 
1H and 15N chemical shifts of A53T α-syn occurred upon addition of 14-3-3ζ. (B). The change in the relative intensity of 
15N-labeled A53T α-syn cross-peaks in the presence of 14-3-3ζ at 1.0:1.0 and 1.0:2.0 molar ratios, relative to the absence of 
14-3-3ζ. The intensities of the contour levels were corrected for dilution effects. Three HSQC spectra were acquired for 
each sample and the data are plotted as the average ± SEM. (C). The spin-spin relaxation rate (R2) for individual backbone 
nitrogens of 15N-labeled A53T α-syn in the absence (blue) and presence (red), at a 1.0:1.0 molar ratio, of unlabeled 14-3-3ζ. 
The transverse (spin-spin) 15N relaxation rate (R2) of 15N-labeled A53T α-syn cross-
peaks in the absence and presence of a molar equivalent of 14-3-3ζ was determined (Fig-
ure 4c). Interaction between the two proteins, even if transient, will alter (most likely in-
crease) the R2 values of the residues involved. On average, there was a slight increase in 
R2 values for A53T α-syn in the presence of 14-3-3ζ which was concentrated in the first 50 
or so amino acids, in agreement with the cross-peak intensity data in Figure 4b, i.e., com-
parison of R2 values in the absence and presence of 14-3-3ζ was consistent with an inter-
action between the two proteins that mainly involved the N-terminal region of A53T. 
The preferential interaction of the N-terminal region of α-syn with 14-3-3ζ is con-
sistent with the in vitro and in-cell NMR data of Burmann et al. [36]. 1H-15N HSQC spectra 
of 15N-labeled α-syn revealed that six molecular chaperones (they did not examine 14-3-3 
proteins or sHsps) ‘commonly recognize a canonical motif in α-synuclein, consisting of 
the N-terminus (12 residues) and a segment (six residues) around Tyr39′. The interaction 
is transient and weak and, inside cells, maintains α-syn in its monomeric, unfolded, and 
functional (i.e., non-amyloidogenic) state. The two interacting N-terminal regions of α-
Figure 4. 1H-15N HSQC NMR spectrum of uniformly 15N-labeled A53T α-syn in the absence and presence of 14-3-3ζ.
(A) Amide region of the 1H-15N HSQC spectrum at 10 ◦C of 15N-labeled A53T α-syn (black) following the addition of one
(green) and two (red) molar equivalents of unlabeled 14-3-3ζ. Assignments are from Dedmon et al. [35]. No change in the
1H and 15N ch mical shifts of A53T α-syn occurred upon addition of 14-3-3ζ. (B) The change in the relative i t nsity of
15N-labeled A53T α-syn cross-p aks in th presence f 14-3-3ζ at 1.0:1.0 and 1.0:2.0 molar ratios, relative to the absence
of 14-3-3ζ. The intensities of the contour levels were corrected for dilution effects. Three HSQC spectra were acquired for
each sample and the data are plotted as the average ± SEM. (C) The spin-spin relaxation rate (R2) for individual backbone
nitrogens of 15N-labeled A53T α-syn in the absence (blue) and presence (red), at a 1.0:1.0 molar ratio, of unlabeled 14-3-3ζ.
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The transverse (spin-spin) 15N relaxation rate (R2) of 15N-labeled A53T α-syn cross-
peaks in the absence and presence of a molar equivalent of 14-3-3ζ was determined
(Figure 4c). Interaction between the two proteins, even if transient, will alter (most likely
increase) the R2 values of the residues involved. On average, there was a slight increase in
R2 values for A53T α-syn in the presence of 14-3-3ζ which was concentrated in the first
50 or so amino acids, in agreement with the cross-peak intensity data in Figure 4b, i.e.,
comparison of R2 values in the absence and presence of 14-3-3ζ was consistent with an
interaction between the two proteins that mainly involved the N-terminal region of A53T.
The preferential interaction of the N-terminal region of α-syn with 14-3-3ζ is consistent
with the in vitro and in-cell NMR data of Burmann et al. [36]. 1H-15N HSQC spectra of
15N-labeled α-syn revealed that six molecular chaperones (they did not examine 14-3-3
proteins or sHsps) ‘commonly recognize a canonical motif in α-synuclein, consisting of
the N-terminus (12 residues) and a segment (six residues) around Tyr39’. The interaction
is transient and weak and, inside cells, maintains α-syn in its monomeric, unfolded, and
functional (i.e., non-amyloidogenic) state. The two interacting N-terminal regions of α-syn
are hydrophobic in nature, consistent with the primary role of hydrophobic interactions
in the interaction of molecular chaperones. Mass spectrometric determination of the
interactome of α-syn in mammalian cells revealed that many molecular chaperones are
involved in interacting with α-syn via its N-terminal region, including 14-3-3ζ, along with
three other 14-3-3 isoforms (ε, γ and θ/τ) [36]. Thus, during intracellular proteostasis, a
diversity of molecular chaperones interacts with a common N-terminal interface of α-syn
to prevent its association and amyloid fibril formation.
The association of α-syn and 14-3-3 proteins intra- and extracellularly has been
demonstrated in other studies. Immunoprecipitation and immunoblotting of rat brain
homogenates revealed co-association of α-syn and 14-3-3 proteins [37]. They also noted that
α-syn and 14-3-3 proteins have significant sequence similarity in their N-terminal regions,
i.e., of L8-E61 in α-syn and L44-S99 in 14-3-3ζ which would facilitate their mutual associa-
tion. Wang et al. [38] determined from a cell biological study that the θ/τ isoform of 14-3-3
complexes to α-syn in a chaperone interaction, thereby preventing α-syn oligomerization
and regulating the cell-to-cell transfer of cytotoxic α-syn. As a result, 14-3-3θ/τ reduces
α-syn cell toxicity and, hence, may play an important role in the pathology associated
with PD.
Recently, Doherty et al. [39] identified that the N-terminal regions G36 to S42 and
K45 to E57, particularly the former, are critical for regulating the aggregation of α-syn
in vitro and in the nematode, C. elegans. These regions align well with those that interact
with 14-3-3ζ and are obvious targets for the development of α-syn aggregation inhibitors.
Furthermore, in the cryoEM-derived structure of the amyloid fibril form of a variant
(residues 1 to 121) of α-syn without the last 19 amino acids of its acidic, proline-rich and
unstructured C-terminal region, K43 to K58 is β-strand 3 that forms the interface between
the two protofibrils in the overall fibrillar structure [40]. From cryoEM and solid-state
NMR experiments on full-length fibrillar α-syn, a similar interface is present, but two
different overall morphologies are formed compared to that for 1-121 α-syn, highlighting
the polymorph nature of the protein in its amyloid fibrillar state [41]. Most of the first
37 residues of α-syn are not observed, presumably because they are disordered and mobile
and therefore not part of the fibril core [40]. Thus, 14-3-3 proteins interacting transiently,
in a chaperone manner, with K43 to K58 of A53T α-syn may preclude the formation of
β-strand 3 (and its dimer association) in the earliest stages of α-syn aggregation.
The cryoEM structures of α-syn fibrils (filaments) extracted from inclusions in the
brains of individuals with multiple system atrophy (MSA) are also polymorphic. They
comprise two types of fibrils that each contain two different protofibrils [42]. The MSA
α-syn fibrils are different from those formed in vitro from recombinant α-syn in terms of
the number and arrangement of β-strands. However, the MSA and recombinant α-syn
structures contain a common interface between the protofibrils involving the N-terminal
region of α-syn. For the MSA α-syn protofibrils, this encompasses Q24 to A56 (twice), G36
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to V63 and L38 to T64. Again, these data are consistent with the role of the N-terminal region
in regulating the self-association of α-syn and its interaction with molecular chaperones
such as 14-3-3ζ.
3. Materials and Methods
Reagents. All reagents were of analytical grade and purchased from Sigma-Aldrich
(Australia). Aβ peptides (1–40 and 1–42) were purchased from Bachem Ltd. (Weil am Rhein,
Germany). In situ and ex situ Thioflavin T (ThT) fluorescence measurements were con-
ducted in black, clear bottom 96 microwell plates (Greiner Bio-One, Baden-Württemberg,
Germany) using SealPlate MiniStrips (Astral Scientific, Australia) to prevent evapora-
tion. Uranyl acetate, used for negative staining of samples for TEM, was obtained from
Agar Scientific (Essex, UK). All solutions were prepared using deionized water purified
to a resistivity of 18.2 MΩ·cm and subsequently filtered through a 0.22 µm membrane
(Millipore, Australia).
Protein expression and purification. The 14-3-3ζ and Tobacco Etch Virus (TEV) protease
plasmid constructs were a kind gift from Prof. James Murphy (Walter and Eliza Hall Insti-
tute of Medical Research, Australia) and Prof. Michael Parker (University of Melbourne,
Australia), respectively. The expression plasmids for WT and A53T α-syn were a gift from
Dr Tim Guilliams (University of Cambridge, UK). Recombinant 14-3-3ζ-His6 fusion pro-
teins were expressed and purified as described previously [8,43,44]. Following purification,
cleavage of the His6 tag was achieved using the TEV protease, and the cleavage products
were purified using Ni-NTA column chromatography (Qiagen). WT and A53T α-syn were
expressed and purified using the protocol of Narhi et al. [45]. 15N-labeled α-syn was
prepared as outlined in Dedmon et al. [35]. Recombinant 15N-labeled Aβ peptides (1–40
and 1–42) were prepared by co-expression with an affibody [46]. The purified proteins
were stored at −20 ◦C.
All protein and peptide concentrations were determined via absorbance measurements
at either 276 nm or 280 nm using a Cary 5000 UV-vis spectrophotometer (Varian Ltd.,
Australia). A molar extinction coefficient (ε) of 5600 M−1 cm−1 was used for WT and A53T
α-syn, measured at 276 nm. An ε of 23,860 M−1 cm−1 was used for 14-3-3ζ, measured at
280 nm.
Dynamic Light Scattering of 14-3-3ζ and α-synuclein. For 14-3-3ζ and α-syn alone or at a
1.0:1.0 molar ratio (7.2 µM) in 50 mM phosphate containing 100 mM NaCl and 2 mM EDTA,
pH 7.4, time-resolved DLS analysis was performed at 37 ◦C using a Zetasizer Nano-ZS
(Malvern Instruments, Worcestershire, UK). The particle diameter-intensity distribution
and mean hydrodynamic diameter were determined from 13 acquired correllograms using
the program CONTIN [47] and the method of cumulants [48], respectively, via Dispersion
Technology Software (Malvern Instruments Ltd., Worcestershire, UK).
Transmission Electron Microscopy imaging of amyloid fibrils formed in vitro. An aliquot of
the protein solutions from in situ ThT assays (6 µL) was transferred onto a carbon-coated
nickel transmission electron microscopy (TEM) grid (SPI Supplies, West Chester, PA, USA).
The grid was then washed using filtered MilliQ water (2 × 10 µL) before negative staining
with uranyl acetate solution (8 µL, 2% w/v, in MilliQ). Between each step and after staining,
excess solvent was removed by filter paper. After staining, the grids were left to air dry.
Grids were viewed on a Philips CM 100 Transmission Electron Microscope (Eindhoven,
Netherlands) between 13,500 and 64,000 times magnification operating at 120 kV.
Chaperone assays to monitor the effect of 14-3-3ζ on amyloid fibril formation of amyloid β and
α-synuclein. All in vitro experiments in which amyloid fibrils were formed from Aβ40 and
Aβ42 or A53T α-syn were undertaken at 37 ◦C in 50 mM phosphate, 100 mM NaCl, and pH
7.4. The formation of amyloid fibrils, in the absence or presence of 14-3-3ζ was assessed by
ThT fluorescence (20 µM, excitation 440 nm, emission 490 nm) using a Fluorostar Optima
plate reader (BMG Labtechnologies, Australia).
Aβ40 and Aβ42 were dissolved in ammonium hydroxide (final concentration 3.8 mM)
and then diluted to 500 µM in water and stored at −80 ◦C. Further dilutions were made in
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50 mM phosphate buffer containing 100 mM NaCl, pH 7.4, to achieve final concentrations
for plate reader aggregation assays. The kinetics of Aβ40 and Aβ42 (15 µM, 100 µL) amyloid
fibril formation, in the presence and absence of 14-3-3ζ, were monitored by the change in
ThT fluorescence.
A53T α-syn and 14-3-3ζ solutions were prepared in 50 mM phosphate buffer contain-
ing 100 mM NaCl, pH 7.4. Each sample of either A53T α-syn (70 µM), 14-3-3ζ (70 µM),
or A53T α-syn and 14-3-3ζ (70 µM of each protein) was separated into four Eppendorf
tubes, each containing 500 µL. All samples were then wrapped in aluminium foil, with
air-holes to aid in air circulation and temperature equilibration. They were incubated
at 37 ◦C and shaken at 200 rpm for 24 h. For each protein solution, samples (2 × 5 µL)
were taken every 2 h and added to 96 well plates (Greiner Bio-One, Baden-Wurttemberg,
Germany) containing ThT (20 µM, 60 µL). The ThT fluorescence of each plate was read at
37 ◦C. Samples (8 µL) were also taken at 0, 4, 10, and 21 h for TEM imaging.
Two-dimensional 1H-15N HSQC NMR spectroscopy of 15N-labeled Aβ40 and unlabeled
14-3-3ζ. Samples of 15N-labeled Aβ40 and 14-3-3ζ were prepared separately in 20 mM
phosphate containing 0.5 mM EDTA and 0.02 % w/v NaN3, pH 7.4. All spectra were
recorded at 5 ◦C on a Bruker Avance 500 NMR spectrometer (Bruker, UK) operating at a
magnetic field strength of 11.7 T and a 1H frequency of 500.1 MHz and a 15N frequency
of 50.7 MHz equipped with 1H-15N, 13C, 2H z-gradient TCI cryoprobe. 1H chemical
shifts were referenced to water as per Cavanagh et al. [49]. Data were processed with
NMRPipe [50] and analyzed with Sparky v. 3.112 [51] software.
Gradient-enhanced two-dimensional 1H-15N heteronuclear single quantum coherence
(HSQC) correlation spectra were acquired using water suppression via a Watergate pulse
sequence. Spectra were acquired with 640 and 64 complex points and spectral widths of
5001.324 Hz and 532.180 Hz for the 1H and 15N dimensions, respectively. The carrier was
set on-resonance with water in the 1H dimension and 16 scans were recorded per increment
for 70 µM Aβ40. Up to four molar equivalences of 14-3-3ζ were then added in identical
buffer, and subsequent NMR spectra were acquired with identical parameters. No chemical
shift changes were observed in the HSQC spectra, and intensity changes were calculated
(following correction for dilution), with error bars indicating the standard deviation in
background noise of the spectra.
Two-dimensional 1H-15N HSQC NMR spectroscopy of 15N-labeled A53T α-synuclein and
unlabeled 14-3-3ζ. All NMR spectra were acquired at 10 ◦C on a Bruker Avance III 700 NMR
spectrometer operating at a magnetic field strength of 16.4 T and an 1H frequency of
700.1 MHz and a 15N frequency of 71.0 MHz equipped with a TXI cryoprobe. Data were
processed with NMRPipe [50] and analyzed with Sparky v. 3.112 [51] software using
previously reported assignments [35,52]. 15N A53T α-syn (100 µM) was dissolved in
50 mM sodium phosphate containing 100 µM NaCl (10% D2O, pH 7.4). DSS (4,4-dimethyl-
4-silapentane-1-sulfonic acid, 0.1%) was used as a chemical shift reference [53]. Three
sensitivity-enhanced 1H-15N HSQC spectra were acquired, with 256 increments, a sweep
width of 25 ppm in the indirect dimension, and 4 scans per increment.
15N spin-spin relaxation rates (R2) were determined for relaxation times of 15.8 and
126.7 ms with a Carr-Purcell-Meiboom-Gill (CPMG) frequency of 1 kHz, encoded as a
1H-15N HSQC with 128 increments and 16 scans per increment, with a recycle delay of
2 s. One equivalent of 14-3-3ζwas then added in identical buffer, resulting in final α-syn
and 14-3-3ζ concentrations of 84 µM, and a second set of NMR spectra were acquired with
identical parameters. No chemical shift changes were observed in the HSQC spectra, and
intensity changes were calculated (following correction for dilution) from the mean of the
three spectra, with error bars indicating the standard error of the mean. All A53T α-syn
cross-peak positions were obtained from an independent HSQC experiment to avoid the
introduction of systematic bias that results from coupled measurements of peak position
and intensity.
Quartz Crystal Microbalance of α-synuclein and 14-3-3ζ interaction. QCM experiments
were performed as outlined in Shammas et al. [54].
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4. Conclusions
Solution-phase NMR spectroscopy has provided detailed characterization of the
regions or interfaces of two disease-related, amyloid fibril-forming proteins, Aβ40 and
α-syn, that interact with the molecular chaperone, 14-3-3ζ. For both Aβ40 and α-syn, the
hydrophobic regions that interact with 14-3-3ζ are integral components of the β-sheet
core within the final amyloid fibrillar structures of Aβ40 and α-syn prepared in vitro, and
in vivo samples isolated from diseased individuals. The implication is that 14-3-3ζ interacts
preferentially with these β-strand-forming regions of Aβ40 and α-syn early along their
aggregation pathway and thereby interferes with their propensity to associate and form a
β-sheet as the first step in amyloid fibril formation. In the case of α-syn, the N-terminal
V40 to K60 region that interacts with 14-3-3ζ mainly encompasses the regions that regulate
the protein’s aggregation [39].
As with sHsp chaperone action, intimate details of the mechanism by which 14-3-3
proteins elicit their chaperone action are not known, and neither are the reasons for the
variation in their ability to inhibit the amorphous and fibrillar aggregation of destabilized
peptides and proteins [7,8,10,31]. The chaperone action of 14-3-3ζ probably arises from
at least partial dissociation of the dimer and exposure of the chaperone interaction site(s)
at the dimer interface [44]. The significant variation in 14-3-3ζ chaperone ability (in this
case, fibril formation of the Aβ peptides and A53T α-syn) is due to a combination of factors
that have parallels with the chaperone action of the ten human sHsps [5,6]: (i) slowly
aggregating target peptides or proteins provide the opportunity for 14-3-3ζ to interact
efficiently, for example, via dissociation and exposure of its chaperone binding site(s);
(ii) the nature of the partially folded intermediate state of the target peptide or protein prior
to it forming the prefibrillar aggregate; (iii) the size/dimensions of the target peptide or
protein. The seven 14-3-3 isoforms have different functional roles in vivo, most of which
have not been elucidated. For example, the θ/τ isoform inhibits α-syn oligomerization
and fibril formation [31,38], whereas the other isoforms, apart from η, are ineffective [31].
Furthermore, 14-3-3θ/τ reduces cell-to-cell transfer of α-syn, as occurs in the pathology of
PD [38]. Similar diverse functionality, and some redundancy, occur within sHsps [5,6].
In conclusion, this study has provided insights into the means by which 14-3-3ζ (and,
presumably, other 14-3-3 isoforms) exerts its chaperone action to inhibit amyloid fibril
formation. The conclusions are generally applicable as there are strong parallels between
the results reported herein and the in vitro and in-cell NMR studies of the interaction of
α-syn with other molecular chaperones [36].
Supplementary Materials: The following are available online. Figure S1: Amyloid fibril formation,
as monitored by ThT fluorescence, of seeded Aβ40 (15 µM) in the absence and presence of 14-3-3ζ at
1.0:1.0–4.0 molar ratios of Aβ40:14-3-3ζ, Figure S2: Amyloid fibril formation of A53T α-syn (70 µM)
in the absence of 14-3-3ζ and at a 1.0:1.0 molar ratio of A53T α-syn:14-3-3ζ, as monitored by ThT
fluorescence and TEM.
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